pregnancy-associated plasma protein A

(redirected from PAPP-A)
Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.
Related to PAPP-A: nuchal translucency

pregnancy-associated plasma protein A

Abbreviation: PAPP-A
A plasma protein that is used as a screening test between 8 and 14 weeks gestation; diminished levels of the protein suggest an increased risk for Down syndrome, intrauterine growth retardation, preeclampsia, and stillbirth.
See also: protein
References in periodicals archive ?
The serum samples corresponding to the DBSs from the main study were thawed and analyzed on the AutoDELFIA for PAPP-A (kit reference B098-201) and free hCG[beta] (kit reference B097-101), as well as for intact hCG (kit reference B082-101), which was measured as a potential explanatory variable for predicting DBS free-hCG[beta] concentrations.
There was no significant difference in PAPP-A concentrations in deceased patients and survivors [4.
To document the relationship between sustained subcutaneous LMWH administration and serum PAPP-A concentration more clearly, we also measured the serum LMWH concentration by high-performance Capillary electrophoresis.
Paradoxically, there is substantial evidence from the clinical perspective, rather than from the theoretical laboratory approach, that PAPP-A is a useful prognostic marker in ACS.
The proteolytic activity of PAPP-A is directed specifically toward insulin-like growth factor (IGF)-binding proteins, and thus it allows the release of active IGF-1 and promotes the proatherogenic effects of IGF-1 (10).
PAPP-A is a zinc-binding metalloproteinase (8) that specifically degrades insulin-like growth factor (IGF)-binding proteins (9,10), thereby allowing unbound/active IGF to bind to cell-surface IGF receptors (11, 12).
PAPP-A has been shown to be present in unstable coronary atherosclerotic plaques (7), and increased circulating PAPP-A concentrations are associated with acute coronary syndromes (ACS) (7,8).